

# Review article: Systemic consequences of coeliac disease

Pilvi Laurikka<sup>1,2</sup> | Laura Kivelä<sup>1,3</sup>  | Kalle Kurppa<sup>4,5</sup>  | Katri Kaukinen<sup>1,2</sup> 

<sup>1</sup>Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland

<sup>2</sup>Department of Internal Medicine, Tampere University Hospital, Tampere, Finland

<sup>3</sup>Children's Hospital, and Paediatric Research Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

<sup>4</sup>Tampere Center for Child, Adolescent and Maternal Health Research, Tampere University and Tampere University Hospital, Tampere, Finland

<sup>5</sup>The University Consortium of Seinäjoki and Seinäjoki Central Hospital, Seinäjoki, Finland

## Correspondence

Katri Kaukinen, Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.

Email: [katri.kaukinen@tuni.fi](mailto:katri.kaukinen@tuni.fi)

## Summary

**Background:** The best-known symptoms of coeliac disease are related to the gastrointestinal tract, but the disease may also present with various systemic manifestations outside the intestine. Some of these consequences may remain permanent in undiagnosed individuals or if the diagnostic delay is prolonged. However, for many of the systemic manifestations, the scientific evidence remains scant and contradictory.

**Aims and Methods:** We conducted a narrative review of the most thoroughly studied and clinically relevant systemic consequences of coeliac disease, especially those that could be prevented or alleviated by early diagnosis. The review is intended particularly for physicians encountering these patients in daily clinical practice.

**Results:** The possible systemic consequences of coeliac disease extend to multiple organ systems, the best studied of which are related to skeletal, reproductive, cardiovascular and neurological systems. Furthermore, the disease is associated with an elevated risk of psychiatric comorbidities, non-Hodgkin lymphomas and intestinal adenocarcinoma.

**Conclusions:** The various systemic consequences of coeliac disease play a significant role in the overall health of patients. Early diagnosis and treatment with a gluten-free diet appear to be beneficial for most, but not all of these conditions. The possible negative metabolic and psychosocial effects of the diet should be acknowledged during follow-up.

## 1 | INTRODUCTION

During the past few decades, coeliac disease has been seen to affect approximately 1% of the population worldwide.<sup>1</sup> Even though the introduction of modern coeliac disease-specific serological tests has lowered the threshold for active case-finding and risk group screening, the clinically multifaceted disease remains underdiagnosed.<sup>2</sup> The best-known 'classic' symptoms of coeliac disease, such as diarrhoea and weight loss, are directly related to the gastrointestinal

tract, which is also the main site at which the disease-associated autoimmunity is considered to occur.<sup>3</sup> However, it is now known that coeliac disease is a systemic disorder which may also present with a variety of extraintestinal manifestations (Figure 1).<sup>4</sup>


The terminology referring to the diverse features of coeliac disease is not straightforward. While many of the symptoms and manifestations are directly associated with the disease and alleviated after commencing a gluten-free diet, others have less evident gluten dependency and treatment response.<sup>5,6</sup> It may also be challenging to

The Handling Editor for this article was Professor Peter Gibson, and it was accepted for publication after full peer-review.

Pilvi Laurikka and Laura Kivelä are equally contributors.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. *Alimentary Pharmacology & Therapeutics* published by John Wiley & Sons Ltd.



**FIGURE 1** Wide range of possible clinical consequences of coeliac disease outside gastrointestinal tract

distinguish persistent symptoms during the diet caused by ongoing gluten intake from those unrelated to coeliac disease. Additionally, several clinical entities, such as autoimmune diseases, have been associated with coeliac disease.<sup>7</sup> Although not actually systemic consequences and probably not preventable by a gluten-free diet,<sup>8,9</sup> these comorbidities may nonetheless increase the overall burden of disease. It should also be noted that the dietary treatment itself may be nutritionally suboptimal and have a detrimental impact on general health.<sup>10,11</sup>

In this review, we discuss the various systemic consequences of coeliac disease, focusing particularly to adult patients and consequences that could possibly be prevented or at least alleviated by a prompt diagnosis and strict gluten-free treatment (Table 1). Unfortunately, for many of these manifestations the scientific evidence remains limited or contradictory. Here we aimed to focus on those consequences that have been studied the most thoroughly, including disturbances of the skeletal, reproductive, cardiovascular and neurological systems, psychiatric comorbidities and malignancies.

## 2 | BONE HEALTH

Reduced bone mineral density (BMD) is a well-documented finding in untreated coeliac disease.<sup>12–15</sup> According to a recent systematic review, osteoporosis can be found in 4%–20% and osteopenia in 10%–50% of men and premenopausal women with coeliac disease.<sup>16</sup> Likewise, 7%–16% of children have been reported to present with reduced BMD at diagnosis.<sup>17–19</sup> The pathogenetic mechanisms are likely complex, including for example, malabsorption of calcium and vitamin D, inflammatory mediators and autoimmunity,<sup>20–22</sup>

which may also partly explain the wide variation in the prevalence figures reported. For example, in some patients decreased BMD can be detected even before the development of significant small-bowel mucosal atrophy.<sup>23</sup> Coeliac disease has also been associated with increased fracture risk compared to that of general population.<sup>24–27</sup>

The current evidence does not support routine screening for osteoporosis of all patients.<sup>28–30</sup> Instead, measurement of BMD could be considered in patients with long diagnostic delay and with clinically or histologically severe disease at diagnosis. Also, other osteoporosis risk factors, such as age, sex, weight and nutritional status, the presence of comorbidities, medications, physical activity and menopausal status in women, affect the risk for osteoporosis.<sup>14,15,29–33</sup> To combine these risk factors to predict the fracture risk in coeliac disease, various clinical tools such as FRAX® score may be useful.<sup>25</sup> The diagnostic workup and evaluation of the severity of osteoporosis follows standard clinical practice.

In most studies, reduced BMD has already improved significantly within 1 year on a gluten-free diet.<sup>17,34,35</sup> However, particularly in adults, recovery may remain partial, while children generally achieve more complete improvement of bone health.<sup>17,34–36</sup> In fact, the early coeliac disease diagnosis might be especially important in paediatric patients, as the peak bone mass is achieved during young adulthood,<sup>37</sup> and thus the bone accrual may remain incomplete if the diagnosis is delayed. Whether the dietary treatment also decreases the fracture risk remains more controversial, as in some studies their frequency has decreased to the level of general population,<sup>27,38,39</sup> whereas in others the risk has remained elevated.<sup>25,26</sup> In a Swedish register-based study,

**TABLE 1** Possible systemic consequences of coeliac disease, estimated level of scientific evidence and suggestions considering their screening and treatment

Systemic consequence	Evidence	Proposed clinical approach
Impaired bone health and increased risk for fractures	Confirmed	<ul style="list-style-type: none"> <li>• Measure BMD especially if severe clinical presentation, long diagnostic delay or poor GFD response, and in patients with additional risk factors for osteoporosis</li> <li>• E.g. FRAX® tool can be used to estimate the fracture risk</li> </ul>
Non-Hodgkin lymphoma and intestinal adenocarcinoma	Confirmed	<ul style="list-style-type: none"> <li>• Repeat duodenal biopsies in non-responsive coeliac disease</li> <li>• Consult experts if malignancy is suspected</li> </ul>
Neurological complaints	Probable	<ul style="list-style-type: none"> <li>• Suspect especially in elderly patients with long diagnostic delay.</li> <li>• Consult specialised unit about the treatment.</li> </ul>
Psychiatric symptoms	Probable	<ul style="list-style-type: none"> <li>• Consult psychiatrist if poor response to strict GFD.</li> <li>• Provide support if high burden of dietary restriction.</li> </ul>
Impaired reproductive health	Probable	<ul style="list-style-type: none"> <li>• Screen coeliac disease in women with unexplained infertility or recurrent miscarriages.</li> <li>• Provide professional dietetic support for coeliac women who are planning pregnancy.</li> </ul>
Decreased cardiovascular health	Controversial	<ul style="list-style-type: none"> <li>• Routine screening due to coeliac disease alone is not recommended.</li> <li>• Possible negative metabolic effects of GFD should be considered in patients with cardiovascular risk factors</li> </ul>

Abbreviations: BMD, bone mineral density; FRAX®, Fracture Risk Assessment Tool; GFD, gluten-free diet.

ongoing fracture risk was associated with slow histological recovery, suggesting that this may be attributable to either a more severe duodenal lesion at diagnosis or poor dietary adherence—or both.<sup>40</sup> Recommendations regarding the importance of sufficient intake of calcium and vitamin D and use of specific medications follow general guidelines. Continuous bone loss during gluten-free diet should lead to the evaluation of dietary adherence and consideration of repeat biopsy.<sup>28</sup> In newly diagnosed coeliac disease, patients with documented osteoporosis, intravenous administration of bisphosphonates may be preferable.<sup>29</sup> To conclude, the association between coeliac disease and reduced BMD and increased fracture risk is well-established, and early coeliac disease diagnosis could be assumed to improve bone health significantly.

### 3 | REPRODUCTIVE HEALTH

Untreated coeliac disease may already affect hormonal balance in childhood, causing, for example, delayed puberty<sup>41</sup> and higher age at menarche.<sup>42</sup> In addition, although the evidence so far is more contradictory, later-in-life women have been suggested to be at increased risk for infertility, miscarriages and pregnancy complications, as well as for early menopause.<sup>42,43</sup> In contrast, the few studies published on reproductive health in men with coeliac disease have reported fertility comparable to that of age-matched controls.<sup>44,45</sup>

Whether there is an association between undiagnosed coeliac disease and infertility, two recent meta-analyses reported contradictory results.<sup>46,47</sup> Although women with a coeliac disease have demonstrated improved fertility rates after initiation of gluten-free diet,<sup>48</sup> neither the presence of untreated coeliac disease nor initiation of the dietary treatment affected reproductive outcomes in

women undergoing in vitro fertilisation.<sup>49</sup> The risk for miscarriages has been reported to be increased in untreated coeliac disease, especially a few years before the eventual diagnosis,<sup>50–52</sup> whereas appropriately treated patients do not seem to differ from controls.<sup>50,51</sup> This may be explained, for instance, by the presence of nutrient deficiencies and non-specific inflammation, as well as coeliac autoantibodies interfering endometrial angiogenesis.<sup>53</sup> However, the true causality and benefits of a gluten-free diet remain debatable as shared genetic risk factors between coeliac disease and miscarriages have also been proposed.<sup>54</sup> Although more evidence is needed, at this point, active screening for coeliac disease seems to be justified in women with unexplained infertility or recurrent miscarriages.<sup>29,55</sup>

Other suggested adverse pregnancy outcomes include stillbirth, intrauterine growth retardation and prematurity.<sup>44,56</sup> These complications have been reported in both untreated and treated patients, and initiation of a gluten-free diet has improved some of the results.<sup>56</sup> Interestingly, high levels of serum coeliac autoantibodies have been associated with foetal growth restriction.<sup>57</sup> However, in another study an association was only reported between untreated coeliac seropositivity and small-for-gestational age in boys, but not with other adverse pregnancy outcomes.<sup>58</sup> Notwithstanding these partly controversial results, in addition to dietary counselling in general, specific focus on a strict gluten-free diet could be beneficial for women with coeliac disease who are pregnant or planning pregnancy.

### 4 | CARDIOVASCULAR HEALTH

Like many other autoimmune diseases,<sup>59</sup> coeliac disease may increase the risk of cardiovascular diseases, for example by chronic inflammation leading to acceleration of atherosclerosis.<sup>60–62</sup> However, the scientific

evidence remains sparse and inconsistent. The risk of coronary heart disease and cerebrovascular disease, for example, appears to be only modest at most,<sup>63–66</sup> but mortality due to cardiovascular events may nevertheless be increased compared with general population.<sup>64</sup> Coeliac disease may also be associated with some non-ischaemic conditions, such as idiopathic dilated cardiomyopathy, but again the results are inconsistent.<sup>67–69</sup> As the scientific evidence remains contradictory, the screening for cardiovascular diseases due to coeliac disease alone is not recommended. Of note, the risk can be affected by the presence of comorbidities such as type 1 diabetes.<sup>70</sup>

The principles in the prevention and treatment of cardiovascular diseases in coeliac disease patients follow general recommendations.<sup>71</sup> The effect of a gluten-free diet has been little studied, but there are some indications of a beneficial effect on carotid intima thickness and serum lipid profile,<sup>61,72,73</sup> as well as on cardiac performance in patients with cardiomyopathy.<sup>74</sup> Paradoxically, the diet may also increase the risk of cardiovascular events, as it often has poor fibre and mineral content and high levels of added sugar and fat.<sup>10,11,75,76</sup> This possibly negative effect should be considered both at diagnosis and during the later follow-up, particularly in patients presenting with other cardiovascular risk factors.<sup>10</sup> As a whole, however, the benefits of a gluten-free diet for the general health and cardiovascular risk of coeliac disease patients seem to outweigh the potential disadvantages.

## 5 | NEUROLOGICAL MANIFESTATIONS

Coeliac disease appears to be associated with certain neurological entities, varying from vague and transient symptoms such as commonly reported headache and 'brain fog' to permanent conditions seriously disturbing daily life.<sup>77</sup> For example, a recent meta-analysis concluded neuropathy and ataxia to be more common among coeliac disease patients than among general population, although there was considerable heterogeneity and increased risk was not seen in all studies.<sup>78</sup> More controversial is the association between coeliac disease and epilepsy,<sup>79,80</sup> except for rare forms of treatment-resistant temporal lobe epilepsy and epilepsy with cerebral calcifications.<sup>81,82</sup> There is also some evidence that untreated coeliac disease may cause cognitive impairment.<sup>83</sup> It is in fact possible that these conditions at least partly belong under the wider umbrella of gluten-related neurological disorders, as there are patients who do not meet the official criteria for coeliac disease but may still benefit from a gluten restriction and express anti-gliadin antibodies or autoantibodies to transglutaminase 6.<sup>84</sup> However, the true association between neurological manifestations of coeliac disease and other gluten-related symptoms, as well as possible shared mechanisms, remain unclear.<sup>85</sup> Given the complex nature of these conditions, low-threshold referral to a specialised centre is recommended.

Gluten-free diet may have at least some beneficial effects on the neurological symptoms, possibly depending on dietary adherence and histological response.<sup>78,79,81,86,87</sup> However, full recovery,

for example, from gluten ataxia is infrequent.<sup>88</sup> Similarly, impaired cognitive functions have been reported also to be overrepresented in treated coeliac disease.<sup>83</sup> Of note, Croall and colleagues found coeliac disease patients with neurological findings to present with white matter abnormalities, supporting the permanent nature of these comorbidities.<sup>89</sup> Studies with larger patient cohorts and control groups would be needed to confirm the effect of gluten-free diet on cognitive function.<sup>90</sup> Altogether, while awaiting more evidence, the often incomplete recovery from gluten-dependent neurological complications emphasises the importance of prompt diagnosis of coeliac disease.

## 6 | MENTAL HEALTH

Establishing the causal associations between coeliac disease and mental health is challenging, as ongoing symptoms may obviously have a negative effect on mood. In any case, many psychiatric illnesses, such as depression, anxiety and eating disorders, seem to be overrepresented at least in untreated patients.<sup>91,92</sup> The biological mechanisms behind this association remains to be ascertained although disturbances in the gut-brain axis and white matter tract changes have been hypothesised.<sup>89,93,94</sup> However, psychiatric comorbidities have been reported to be increased also among treated coeliac disease patients.<sup>92,95,96</sup> The underlying pathogenesis and role of gluten-free diet on psychological symptoms and quality of life are currently unclear due to the paucity of the long-term follow-up studies.<sup>97,98</sup> Altogether, patients' mental health and the presence of psychiatric symptoms require attention when coeliac disease is diagnosed. Low-threshold psychiatric consultation should be provided at the latest when the symptoms persist despite successful treatment or there is a suspicion of concomitant psychiatric disease.

An additional issue to be considered is that a gluten-free diet may be difficult to maintain and socially restrictive and therefore give rise, for example, to increased anxiety and emotional distress.<sup>99</sup> In fact, Shah et al. reported coeliac disease patients to have as high a treatment burden as those dependent on dialysis due to end-stage renal disease.<sup>100</sup> Patients with a psychiatric comorbidity may find the strict dietary restriction particularly burdensome<sup>101</sup> and the often-observed incomplete clinical response may further impair motivation for treatment.<sup>102–104</sup> Conversely, even well-responding patients may be at risk for increased anxiety if their approach towards the diet is hypervigilant.<sup>105,106</sup>

## 7 | MALIGNANCIES

A well-known although exceptionally rare complication of non-responsive (refractory) coeliac disease is enteropathy-associated T-cell lymphoma (EATL), a subtype of non-Hodgkin lymphoma which is estimated to affect 0.1%–3.2% of all coeliac disease patients.<sup>107–109</sup> An increased risk for other subtypes of non-Hodgkin lymphoma as well as intestinal adenocarcinoma has also

been recognised.<sup>107,109,110</sup> In contrast, the association between coeliac disease and overall cancer risk remains debatable and the prevalence figures for any cancer in coeliac disease have varied between 2.3% and 15.9%.<sup>107-109,111</sup> In fact, the risk for breast cancer may even be reduced.<sup>109,112-114</sup> In some studies, the risk for malignancies has been increased mainly during the first few years after coeliac disease diagnosis.<sup>111,113,115</sup> This may be at least partly because newly diagnosed patients are often also evaluated with lower threshold for malignancies—especially in case of unsatisfactory treatment response. Conversely, symptoms of cancer may lead to extensive investigations, including gastrointestinal endoscopies or serological testing for coeliac disease.

Another factor possibly affecting the reported risk for malignancies in coeliac disease is that the clinically recognised forms of the disease with higher risk for malignant complications have been overrepresented, especially in earlier studies.<sup>1,116</sup> In recent decades, advances in non-invasive diagnostics and active screening have resulted in earlier diagnosis and mitigated clinical features.<sup>117,118</sup> Simultaneously, adherence to a strict dietary treatment has become easier due to better availability of gluten-free products.<sup>119</sup> These timely changes could explain some of the discrepancies in the overall cancer risk between studies.

The increased risk, especially for non-Hodgkin lymphoma and intestinal adenocarcinoma, nevertheless persists and should be kept in mind particularly in elderly patients,<sup>66,111</sup> as well as in those presenting with a long diagnostic delay or severe malabsorption.<sup>120</sup> Naturally, factors affecting cancer risk in general, such as obesity, smoking, alcohol consumption and other lifestyle factors also apply to coeliac disease patients. Of note, the patients seem to be less often smokers<sup>121</sup> and may present more often with favourable BMI than their non-coeliac counterparts.<sup>75,122,123</sup> It is also good to remember that coeliac disease is associated with autoimmune comorbidities and chromosomal abnormalities, which may increase the risk for certain malignancies.<sup>124-126</sup> The overrepresentation of malignancies is likely a major reason for the increased mortality rate in coeliac disease patients.<sup>64,127-129</sup>

## 8 | CONCLUSIONS

Coeliac disease has traditionally been considered primarily a gastrointestinal disorder, which may result in underestimation of its effects on various extraintestinal organs and malignancy risk. Unfortunately, the current scientific evidence remains scarce and heterogeneous, making it difficult to estimate the effects of coeliac disease screening in preventing these systemic manifestations. These consequences also play a significant role in the overall health and mortality of coeliac disease patients, together with lifestyle factors, the presence of comorbidities and successful adherence to a gluten-free diet.<sup>64,127-129</sup> Early diagnosis and dietary treatment may protect against coeliac-related impaired bone health, neurological symptoms and malignancies, and also at least some of the hormonal complications seem to be reversible on a strict gluten-free diet. The

possible negative effects of a strict dietary restriction on cardiovascular health and psychological well-being should also receive special consideration during long-term follow-up.

## ACKNOWLEDGEMENT

Figure created with [Biorender.com](https://biorender.com)

## AUTHOR CONTRIBUTIONS

**Pilvi Laurikka:** Conceptualization (equal); writing – original draft (equal). **Laura Kivelä:** Conceptualization (equal); writing – original draft (equal). **Kalle Kurppa:** Conceptualization (equal); writing – review and editing (equal). **Katri Kaukinen:** Conceptualization (equal); project administration (lead); writing – review and editing (equal).

## CONFLICT OF INTEREST

None.

## AUTHORSHIP

*Author contributions:* Pilvi Laurikka and Laura Kivelä drafted the manuscript and performed the literature review with equal contribution. Kalle Kurppa and Katri Kaukinen edited and reviewed the manuscript and contributed with additional references. All authors conceptualised the review and approved the final version.

## DATA AVAILABILITY STATEMENT

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

## ORCID

Laura Kivelä  <https://orcid.org/0000-0001-7959-7628>

Kalle Kurppa  <https://orcid.org/0000-0003-4757-2164>

Katri Kaukinen  <https://orcid.org/0000-0002-5046-8133>

## REFERENCES

1. Singh P, Arora A, Strand TA, Leffler DA, Catassi C, Green PH, et al. Global prevalence of celiac disease: systematic review and meta-analysis. *Clin Gastroenterol Hepatol*. 2018;16:823–836.e2. <https://doi.org/10.1016/J.CGH.2017.06.037>
2. Catassi C, Gatti S, Lionetti E. World perspective and celiac disease epidemiology. *Dig Dis*. 2015;33:141–6. <https://doi.org/10.1159/000369518>
3. Lebowitz B, Sanders DS, Green PHR. Coeliac disease. *Lancet*. 2018;391:70–81. [https://doi.org/10.1016/S0140-6736\(17\)31796-8](https://doi.org/10.1016/S0140-6736(17)31796-8)
4. Therrien A, Kelly CP, Silvester JA. Celiac disease: extraintestinal manifestations and associated conditions. *J Clin Gastroenterol*. 2020;54:8–21. <https://doi.org/10.1097/MCG.0000000000001267>
5. Sansotta N, Amirikian K, Guandalini S, Jericho H. Celiac disease symptom resolution: effectiveness of the gluten-free diet. *J Pediatr Gastroenterol Nutr*. 2018;66:48–52. <https://doi.org/10.1097/MPG.0000000000001634>
6. Murray JA, Watson T, Clearman B, Mitros F. Effect of a gluten-free diet on gastrointestinal symptoms in celiac disease. *Am J Clin Nutr*. 2004;79:669–73. <https://doi.org/10.1093/AJCN/79.4.669>
7. Lundin KEA, Wijmenga C. Coeliac disease and autoimmune disease-genetic overlap and screening. *Nat Rev Gastroenterol*

- Hepatol. 2015;12:507–15. <https://doi.org/10.1038/NRGAS.TRO.2015.136>
8. Sategna Guidetti C, Solerio E, Scaglione N, Aimo G, Mengozzi G. Duration of gluten exposure in adult coeliac disease does not correlate with the risk for autoimmune disorders. *Gut*. 2001;49:502–5. <https://doi.org/10.1136/GUT.49.4.502>
  9. Viljamaa M, Kaukinen K, Huhtala H, Kyrönpalo S, Rasmussen M, Collin P. Coeliac disease, autoimmune diseases and gluten exposure. *Scand J Gastroenterol*. 2005;40:437–43. <https://doi.org/10.1080/00365520510012181>
  10. Wild D, Robins GG, Burley VJ, Howdle PD. Evidence of high sugar intake, and low fibre and mineral intake, in the gluten-free diet. *Aliment Pharmacol Ther*. 2010;32:573–81. <https://doi.org/10.1111/J.1365-2036.2010.04386.X>
  11. Shepherd SJ, Gibson PR. Nutritional inadequacies of the gluten-free diet in both recently-diagnosed and long-term patients with coeliac disease. *J Hum Nutr Diet*. 2013;26:349–58. <https://doi.org/10.1111/JHN.12018>
  12. Zanchetta MB, Costa F, Longobardi V, Longarini G, Mazure RM, Moreno ML, et al. Significant bone microarchitecture impairment in premenopausal women with active celiac disease. *Bone*. 2015;76:149–57. <https://doi.org/10.1016/j.bone.2015.03.005>
  13. Mustalahti K, Collin P, Sievänen H, Salmi J, Mäki M. Osteopenia in patients with clinically silent coeliac disease warrants screening. *Lancet*. 1999;354(9180):744–5. [https://doi.org/10.1016/S0140-6736\(99\)01990-X](https://doi.org/10.1016/S0140-6736(99)01990-X)
  14. Corazza G, di Sario A, Cecchetti L, Jorizzo RA, di Stefano M, Minguzzi L, et al. Influence of pattern of clinical presentation and of gluten-free diet on bone mass and metabolism in adult coeliac disease. *Bone*. 1996;18(6):525–30. [https://doi.org/10.1016/8756-3282\(96\)00071-3](https://doi.org/10.1016/8756-3282(96)00071-3)
  15. Mazure R, Vazquez H, Gonzalez D, Mautalen C, Soifer G, Cataldi M, et al. Bone mineral affection in asymptomatic adult patients with celiac disease. *Am J Gastroenterol*. 1994;91:726–30.
  16. Ganji R, Moghbeli M, Sadeghi R, Bayat G, Ganji A. Prevalence of osteoporosis and osteopenia in men and premenopausal women with celiac disease: a systematic review. *Nutr J*. 2019;18:9. <https://doi.org/10.1186/S12937-019-0434-6>
  17. Tau C, Mautalen C, de Rosa S, Roca A, Valenzuela X. Bone mineral density in children with celiac disease. Effect of a gluten-free diet. *Eur J Clin Nutr*. 2006;60:358–63. <https://doi.org/10.1038/SJ.EJCN.1602323>
  18. Webster J, Vajravelu M, Choi C, Zemel B, Verma R. Prevalence of and risk factors for low bone mineral density in children with celiac disease. *Clin Gastroenterol Hepatol*. 2019;17:1509–14. <https://doi.org/10.1016/j.cgh.2018.10.035>
  19. Turner J, Pellerin G, Mager D. Prevalence of metabolic bone disease in children with celiac disease is independent of symptoms at diagnosis. *J Pediatr Gastroenterol Nutr*. 2009;49:589–93. <https://doi.org/10.1097/MPG.0B013E31819CA18E>
  20. Amarasekara D, Yu J, Rho J. Bone loss triggered by the cytokine network in inflammatory autoimmune diseases. *J Immunol Res* 2015;2015:832127. doi:<https://doi.org/10.1155/2015/832127>, 1, 12
  21. Sugai E, Ch�rňavsky A, Pedreira S, Smecuol E, Vazquez H, Niveloni S, et al. Bone-specific antibodies in sera from patients with celiac disease: characterization and implications in osteoporosis. *J Clin Immunol*. 2002;22(6):353–62. <https://doi.org/10.1023/A:1020786315956>
  22. Zylberberg HM, Lebowhl B, Green PHR. Celiac disease-musculoskeletal manifestations and mechanisms in children to adults. *Curr Osteoporos Rep*. 2018;16:754–62. <https://doi.org/10.1007/S11914-018-0488-Y>
  23. Kurppa K, Collin P, Sievänen H, Huhtala H, Mäki M, Kaukinen K. Gastrointestinal symptoms, quality of life and bone mineral density in mild enteropathic coeliac disease: a prospective clinical trial. *Scand J Gastroenterol*. 2010;45:305–14. <https://doi.org/10.3109/00365520903555879>
  24. Heikkilä K, Heliövaara M, Impivaara O, Kröger H, Knekt P, Rissanen H, et al. Celiac disease autoimmunity and hip fracture risk: findings from a prospective cohort study. *J Bone Miner Res*. 2015;30(4):630–6. <https://doi.org/10.1002/JBMR.2380>
  25. Duerksen DR, Lix LM, Johansson H, McCloskey EV, Harvey NC, Kanis JA, et al. Fracture risk assessment in celiac disease: a registry-based cohort study. *Osteoporos Int*. 2021;32(1):93–9. <https://doi.org/10.1007/S00198-020-05579-7>
  26. Heikkilä K, Pearce J, Mäki M, Kaukinen K. Celiac disease and bone fractures: a systematic review and meta-analysis. *J Clin Endocrinol Metab*. 2015;100(1):25–34. <https://doi.org/10.1210/JC.2014-1858>
  27. Pinto-Sánchez MI, Mohaidle A, Baistrocchi A, Matoso D, Vázquez H, González A, et al. Risk of fracture in celiac disease: gender, dietary compliance, or both? *World J Gastroenterol*. 2011;17:3035–42. <https://doi.org/10.3748/WJG.V17.I25.3035>
  28. Ludvigsson JF, Bai JC, Biagi F, Card TR, Ciacci C, Ciclitira PJ, et al. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. *Gut*. 2014;63:1210–28. <https://doi.org/10.1136/GUTJNL-2013-306578>
  29. Al-Toma A, Volta U, Auricchio R, Castillejo G, Sanders DS, Cellier C, et al. European Society for the Study of coeliac disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. *United European Gastroenterol J*. 2019;7:583–613. <https://doi.org/10.1177/2050640619844125>
  30. Fouda MA, Khan AA, Sultan M, Rios LP, McAssey K, Armstrong D. Evaluation and management of skeletal health in celiac disease: position statement. *Can J Gastroenterol*. 2012;26:819–29. <https://doi.org/10.1155/2012/823648>
  31. Dontas IA, Yiannakopoulos CK. Risk factors and prevention of osteoporosis-related fractures. *J Musculoskelet Neuronal Interact*. 2007;7:268–72.
  32. Galli G, Lahner E, Conti L, Esposito G, Sacchi MC, Annibale B. Risk factors associated with osteoporosis in a cohort of prospectively diagnosed adult coeliac patients. *United European Gastroenterol J*. 2018;6:1161–8. <https://doi.org/10.1177/2050640618784340>
  33. Walker M, Williams J, Lewis S, Bai J, Lebowhl B, Green P. Measurement of forearm bone density by dual energy X-ray absorptiometry increases the prevalence of osteoporosis in men with celiac disease. *Clin Gastroenterol Hepatol*. 2020;18:99–106. <https://doi.org/10.1016/j.cgh.2019.03.049>
  34. McFarlane X, Bhalla A, Robertson D. Effect of a gluten free diet on osteopenia in adults with newly diagnosed coeliac disease. *Gut*. 1996;39:180–4. <https://doi.org/10.1136/GUT.39.2.180>
  35. Zanchetta MB, Longobardi V, Costa F, Longarini G, Mazure RM, Moreno ML, et al. Impaired bone microarchitecture improves after one year on gluten-free diet: a prospective longitudinal HRpQCT study in women with celiac disease. *J Bone Miner Res*. 2017;32:135–42. <https://doi.org/10.1002/JBMR.2922>
  36. Canova C, Pitter G, Zanier L, Simonato L, Michaelsson K, Ludvigsson JF. Risk of fractures in youths with celiac disease—a population-based study. *J Pediatr*. 2018;198:117–20. <https://doi.org/10.1016/j.jpeds.2018.02.070>
  37. Weaver CM, Gordon CM, Janz KF, Kalkwarf HJ, Lappe JM, Lewis R, et al. The National Osteoporosis Foundation's position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. *Osteoporos Int*. 2016;27:1281–386. <https://doi.org/10.1007/S00198-015-3440-3>
  38. Pasternack C, Koskinen I, Hervonen K, Kaukinen K, Järvelin J, Reunala T, et al. Risk of fractures in dermatitis herpetiformis and coeliac disease: a register-based study. *Scand J Gastroenterol*. 2019;54(7):843–8. <https://doi.org/10.1080/00365521.2019.1636132>

39. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. *Am J Epidemiol*. 2002;156(1):1–10. <https://doi.org/10.1093/AJE/KWF007>
40. Lebwohl B, Michaëlsson K, Green P, Ludvigsson J. Persistent mucosal damage and risk of fracture in celiac disease. *J Clin Endocrinol Metab*. 2014;99:609–16. <https://doi.org/10.1210/JC.2013-3164>
41. Jericho H, Sansotta N, Guandalini S. Extraintestinal manifestations of celiac disease: effectiveness of the gluten-free diet. *J Pediatr Gastroenterol Nutr*. 2017;65:75–9. <https://doi.org/10.1097/MPG.0000000000001420>
42. Santonicola A, Iovino P, Cappello C, Capone P, Andreozzi P, Ciacci C. From menarche to menopause: the fertile life span of celiac women. *Menopause*. 2011;18:1125–30. <https://doi.org/10.1097/GME.0B013E3182188421>
43. Casella G, Orfanotti G, Giacomantonio L, Bella CD, Crisafulli V, Villanacci V, et al. Celiac disease and obstetrical-gynecological contribution. *Gastroenterol Hepatol Bed Bench*. 2016;9:241–9. <https://doi.org/10.22037/ghfb.v0i0.1013>
44. Pogačar MŠ, Vlaisavljević V, Turk E, Mičetić-Turk D. Reproductive complications in celiac disease patients in Slovenia. *Eur J Obstet Gynecol Reprod Biol*. 2019;238:90–4. <https://doi.org/10.1016/J.EJOGRB.2019.05.015>
45. Zugna D, Richiardi L, Akre O, Stephansson O, Ludvigsson JF. Celiac disease is not a risk factor for infertility in men. *Fertil Steril*. 2011;95:1709.e1–13.e3. <https://doi.org/10.1016/J.FERTNSTERT.2011.01.132>
46. Castaño M, Gómez-Gordo R, Cuevas D, Núñez C. Systematic review and meta-analysis of prevalence of coeliac disease in women with infertility. *Nutrients*. 2019;11:1950. <https://doi.org/10.3390/NU11081950>
47. Glimberg I, Haggård L, Lebwohl B, Green PHR, Ludvigsson JF. The prevalence of celiac disease in women with infertility—a systematic review with meta-analysis. *Reprod Med Biol*. 2021;20:224–33. <https://doi.org/10.1002/RMB2.12374>
48. Alecsandru D, López-Palacios N, Castaño M, Aparicio P, García-Velasco JA, Núñez C. Exploring undiagnosed celiac disease in women with recurrent reproductive failure: the gluten-free diet could improve reproductive outcomes. *Am J Reprod Immunol*. 2020;83:e13209. <https://doi.org/10.1111/AJI.13209>
49. Juneau CR, Franasiak JM, Goodman LR, Marin D, Scott K, Morin SJ, et al. Celiac disease is not more prevalent in patients undergoing in vitro fertilization and does not affect reproductive outcomes with or without treatment: a large prospective cohort study. *Fertil Steril*. 2018;110:437–42. <https://doi.org/10.1016/J.FERTNSTERT.2018.03.030>
50. Grode L, Bech BH, Plana-Ripoll O, Bliddal M, Agerholm IE, Humaidan P, et al. Reproductive life in women with celiac disease: a nationwide, population-based matched cohort study. *Hum Reprod*. 2018;33:1538–47. <https://doi.org/10.1093/HUMREP/DEY214>
51. Tersigni C, Castellani R, de waure C, Fattorossi A, De Spirito M, Garbarrini A, et al. Celiac disease and reproductive disorders: meta-analysis of epidemiologic associations and potential pathogenic mechanisms. *Hum Reprod Update* 2014;20:582–93. doi:<https://doi.org/10.1093/HUMUPD/DMU007>
52. Moleski S, Lindenmeyer C, Veloski J, Miller RS, Miller CL, Kastenberg D, et al. Increased rates of pregnancy complications in women with celiac disease. *Ann Gastroenterol*. 2015;28:236–40.
53. di Simone N, Gratta M, Castellani R, D'Ippolito S, Specchia M, Scambia G, et al. Celiac disease and reproductive failures: an update on pathogenic mechanisms. *Am J Reprod Immunol*. 2021;85:e13334. <https://doi.org/10.1111/AJI.13334>
54. D'Ippolito S, Gasbarrini A, Castellani R, Rocchetti S, Sisti LG, Scambia G, et al. Human leukocyte antigen (HLA) DQ2/DQ8 prevalence in recurrent pregnancy loss women. *Autoimmun Rev*. 2016;15:638–43. <https://doi.org/10.1016/J.AUTREV.2016.02.009>
55. Downey L, Houten R, Murch S, Longson D, Guideline Development Group. Recognition, assessment, and management of coeliac disease: summary of updated NICE guidance. *BMJ*. 2015;351:h4513. <https://doi.org/10.1136/BMJ.H4513>
56. Saccone G, Berghella V, Sarno L, Maruotti GM, Cetin I, Greco L, et al. Celiac disease and obstetric complications: a systematic review and metaanalysis. *Am J Obstet Gynecol*. 2016;214:225–34. <https://doi.org/10.1016/J.AJOG.2015.09.080>
57. Kiefte-De Jong JC, Jaddoe VWV, Uitterlinden AG, Steegers EAP, Willemsen SP, Hofman A, et al. Levels of antibodies against tissue transglutaminase during pregnancy are associated with reduced fetal weight and birth weight. *Gastroenterology*. 2013;144:726–35.e2. <https://doi.org/10.1053/J.GASTRO.2013.01.003>
58. Celdir MG, Choung RS, Rostamkolaei SK, Jansson-Knodell CL, King KS, Larson JJ, et al. Reproductive characteristics and pregnancy outcomes in hidden celiac disease autoimmunity. *Am J Gastroenterol*. 2021;116:593–9. <https://doi.org/10.14309/AJG.0000000000001148>
59. Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, et al. Cardiovascular disease in autoimmune rheumatic diseases. *Autoimmun Rev*. 2013;12:1004–15. <https://doi.org/10.1016/J.AUTREV.2013.03.013>
60. Korkmaz H, Sozen M, Kebapcilar L. Increased arterial stiffness and its relationship with inflammation, insulin, and insulin resistance in celiac disease. *Eur J Gastroenterol Hepatol*. 2015;27:1193–9. <https://doi.org/10.1097/MEG.0000000000000437>
61. de Marchi S, Chiarioni G, Prior M, Arosio E. Young adults with coeliac disease may be at increased risk of early atherosclerosis. *Aliment Pharmacol Ther*. 2013;38:162–9. <https://doi.org/10.1111/APT.12360>
62. Wolf D, Ley K. Immunity and inflammation in atherosclerosis. *Circ Res*. 2019;124:315–27. <https://doi.org/10.1161/CIRCRESAHA.118.313591>
63. Heikkilä K, Koskinen OA, Agarwal A, Tikkinen KAO, Mäki M, Kaukinen K. Associations of coeliac disease with coronary heart disease and cerebrovascular disease: a systematic review and meta-analysis. *Nutr Metab Cardiovasc Dis*. 2015;25:816–31. <https://doi.org/10.1016/J.NUMECD.2015.05.004>
64. Lebwohl B, Green P, Söderling J, Roelstraete B, Ludvigsson J. Association between celiac disease and mortality risk in a Swedish population. *JAMA*. 2020;323:1277–85. <https://doi.org/10.1001/JAMA.2020.1943>
65. Heikkilä K, Rissanen H, Heliövaara M, Knekt P, Mäki M, Kaukinen K. Associations of tissue transglutaminase antibody seropositivity with coronary heart disease: findings from a prospective cohort study. *Nutr Metab Cardiovasc Dis*. 2017;27:817–21. <https://doi.org/10.1016/J.NUMECD.2017.06.005>
66. Kärhus LL, Skaaby T, Petersen J, Madsen AL, Thuesen BH, Schwarz P, et al. Long-term consequences of undiagnosed celiac seropositivity. *Am J Gastroenterol*. 2020;115:1681–8. <https://doi.org/10.14309/AJG.0000000000000737>
67. Curione M, Barbato M, de Biase L, Viola F, Lo Russo L, Cardi E. Prevalence of coeliac disease in idiopathic dilated cardiomyopathy. *Lancet*. 1999;354:222–3. [https://doi.org/10.1016/S0140-6736\(99\)01501-9](https://doi.org/10.1016/S0140-6736(99)01501-9)
68. Fonager K, Sorensen HT, Norgard B, Thulstrup AM. Cardiomyopathy in Danish patients with coeliac disease. *Lancet*. 1999;354:1561. [https://doi.org/10.1016/S0140-6736\(05\)76595-8](https://doi.org/10.1016/S0140-6736(05)76595-8)
69. Emilsson L, Andersson B, Elfström P, Green PHR, Ludvigsson JF. Risk of idiopathic dilated cardiomyopathy in 29000 patients with celiac disease. *J Am Heart Assoc*. 2012;1:e001594. <https://doi.org/10.1161/JAHA.112.001594>

70. Pitocco D, Giubilato S, Martini F, Zaccardi F, Pazzano V, Manto A, et al. Combined atherogenic effects of celiac disease and type 1 diabetes mellitus. *Atherosclerosis*. 2011;217:531–5. <https://doi.org/10.1016/j.atherosclerosis.2011.04.042>
71. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J*. 2020;41:407–77. <https://doi.org/10.1093/eurheartj/ehz425>
72. Demir AM, Kuloğlu Z, Yaman A, Fitöz S, Nergizoğlu G, Kansu A. Carotid intima-media thickness and arterial stiffness as early markers of atherosclerosis in pediatric celiac disease. *Turk J Pediatr*. 2016;58:172–9. <https://doi.org/10.24953/turkjped.2016.02.008>
73. Brar P, Kwon GY, Holleran S, Bai D, Tall AR, Ramakrishnan R, et al. Change in lipid profile in celiac disease: beneficial effect of gluten-free diet. *Am J Med*. 2006;119:786–90. <https://doi.org/10.1016/j.amjmed.2005.12.025>
74. Curione M, Barbato M, Viola F, Francia P, de Biase L, Cucchiara S. Idiopathic dilated cardiomyopathy associated with coeliac disease: the effect of a gluten-free diet on cardiac performance. *Dig Liver Dis*. 2002;34:866–9. [https://doi.org/10.1016/S1590-8658\(02\)80258-4](https://doi.org/10.1016/S1590-8658(02)80258-4)
75. Kabbani TA, Goldberg A, Kelly CP, Pallav K, Tariq S, Peer A, et al. Body mass index and the risk of obesity in coeliac disease treated with the gluten-free diet. *Aliment Pharmacol Ther*. 2012;35:723–9. <https://doi.org/10.1111/j.1365-2036.2012.05001.x>
76. Tortora R, Capone P, de Stefano G, Imperatore N, Gerbino N, Donetto S, et al. Metabolic syndrome in patients with coeliac disease on a gluten-free diet. *Aliment Pharmacol Ther*. 2015;41:352–9. <https://doi.org/10.1111/APT.13062>
77. Trovato CM, Raucci U, Valitutti F, Montuori M, Villa MP, Cucchiara S, et al. Neuropsychiatric manifestations in celiac disease. *Epilepsy Behav*. 2019;99:106393. <https://doi.org/10.1016/j.yebeh.2019.06.036>
78. Mearns E, Taylor A, Thomas Craig K, Puglielli S, Leffler D, Sanders D, et al. Neurological manifestations of neuropathy and ataxia in celiac disease: a systematic review. *Nutrients*. 2019;11:380. <https://doi.org/10.3390/nu11020380>
79. Bashiri H, Afshari D, Babaei N, Ghadami M. Celiac disease and epilepsy: the effect of gluten-free diet on seizure control. *Adv Clin Exp Med*. 2016;25:751–4. <https://doi.org/10.17219/ACEM/43585>
80. Canova C, Ludvigsson J, Barbiellini Amidei C, Zanier L, Zingone F. The risk of epilepsy in children with celiac disease: a population-based cohort study. *Eur J Neurol*. 2020;27:1089–95. <https://doi.org/10.1111/ENE.14160>
81. Gobbi G. Coeliac disease, epilepsy and cerebral calcifications. *Brain and Development*. 2005;27:189–200. <https://doi.org/10.1016/j.braindev.2004.05.003>
82. Peltola M, Kaukinen K, Dastidar P, Haimila K, Partanen J, Haapala AM, et al. Hippocampal sclerosis in refractory temporal lobe epilepsy is associated with gluten sensitivity. *J Neurol Neurosurg Psychiatry*. 2009;80:626–30. <https://doi.org/10.1136/jnnp.2008.148221>
83. Croall I, Tooth C, Venneri A, Poyser C, Sanders DS, Hoggard N, et al. Cognitive impairment in coeliac disease with respect to disease duration and gluten-free diet adherence: a pilot study. *Nutrients*. 2020;12:2028. <https://doi.org/10.3390/nu12072028>
84. Hadjivassiliou M, Aeschlimann P, Sanders DS, Mäki M, Kaukinen K, Grunewald RA, et al. Transglutaminase 6 antibodies in the diagnosis of gluten ataxia. *Neurology*. 2013;80:1740–5. <https://doi.org/10.1212/WNL.0b013e3182919070>
85. Rouvroye MD, Zis P, van Dam AM, Rozemuller AJM, Bouma G, Hadjivassiliou M. The neuropathology of gluten-related neurological disorders: a systematic review. *Nutrients*. 2020;12:822. <https://doi.org/10.3390/nu12030822>
86. Lichtwark I, Newnham E, Robinson S, Shepherd SJ, Hosking P, Gibson PR, et al. Cognitive impairment in coeliac disease improves on a gluten-free diet and correlates with histological and serological indices of disease severity. *Aliment Pharmacol Ther*. 2014;40:160–70. <https://doi.org/10.1111/APT.12809>
87. Zis P, Sarrigiannis PG, Rao DG, Hadjivassiliou M. Gluten neuropathy: prevalence of neuropathic pain and the role of gluten-free diet. *J Neurol*. 2018;265:2231–6. <https://doi.org/10.1007/S00415-018-8978-5>
88. Zis P, Hadjivassiliou M. Treatment of neurological manifestations of gluten sensitivity and coeliac disease. *Curr Treat Options Neurol*. 2019;21:10. <https://doi.org/10.1007/S11940-019-0552-7>
89. Croall I, Sanders D, Hadjivassiliou M, Hoggard N. Cognitive deficit and white matter changes in persons with celiac disease: a population-based study. *Gastroenterology*. 2020;158(8):2112–22. <https://doi.org/10.1053/J.GASTRO.2020.02.028>
90. Makhlof S, Messelmani M, Zaouali J, Mrissa R. Cognitive impairment in celiac disease and non-celiac gluten sensitivity: review of literature on the main cognitive impairments, the imaging and the effect of gluten free diet. *Acta Neurol Belg*. 2018;118:21–7. <https://doi.org/10.1007/S13760-017-0870-Z>
91. Sharma N, Singh K, Senapati S. Celiac disease poses significant risk in developing depression, anxiety, headache, epilepsy, panic disorder, dysthymia: a meta-analysis. *Indian J Gastroenterol*. 2021;40:453–62. <https://doi.org/10.1007/S12664-021-01215-2>
92. Clappison E, Hadjivassiliou M, Zis P. Psychiatric manifestations of coeliac disease, a systematic review and meta-analysis. *Nutrients*. 2020;12:142. <https://doi.org/10.3390/nu12010142>
93. Parisi P. The relationship between mucosal damage in celiac disease and the risk of neurological and psychiatric conditions is much more complex than previously thought. *Eur J Neurol*. 2018;25:797–8. <https://doi.org/10.1111/ENE.13614>
94. Fiorentino M, Sapone A, Senger S, Camhi SS, Kadzielski SM, Buie TM, et al. Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. *Mol Autism*. 2016;7:49. <https://doi.org/10.1186/S13229-016-0110-Z>
95. Lebowitz B, Haggård L, Emilsson L, Söderling J, Roelstraete B, Butwicka A, et al. Psychiatric disorders in patients with a diagnosis of celiac disease during childhood from 1973 to 2016. *Clin Gastroenterol Hepatol*. 2021;19:2093–101.e13. <https://doi.org/10.1016/j.cgh.2020.08.018>
96. Alkhayyat M, Qapaja T, Aggarwal M, Almomani A, Abureesh M, al-otoom O, et al. Epidemiology and risk of psychiatric disorders among patients with celiac disease: a population-based national study. *J Gastroenterol Hepatol*. 2021;36:2165–70. <https://doi.org/10.1111/JGH.15437>
97. Majsiak E, Choina M, Golicki D, Gray AM, Cukrowska B. The impact of symptoms on quality of life before and after diagnosis of coeliac disease: the results from a polish population survey and comparison with the results from the United Kingdom. *BMC Gastroenterol*. 2021;21:99. <https://doi.org/10.1186/S12876-021-01673-0>
98. Canova C, Rosato I, Marsilio I, Valiante F, Zorzetto V, Cataudella G, et al. Quality of life and psychological disorders in coeliac disease: a prospective multicentre study. *Nutrients*. 2021;13(9):3233. <https://doi.org/10.3390/nu13093233>
99. Sainsbury K, Marques MM. The relationship between gluten free diet adherence and depressive symptoms in adults with coeliac disease: a systematic review with meta-analysis. *Appetite*. 2018;120:578–88. <https://doi.org/10.1016/j.appet.2017.10.017>
100. Shah S, Akbari M, Vanga R, Kelly CP, Hansen J, Theethira T, et al. Patient perception of treatment burden is high in celiac disease compared with other common conditions. *Am J Gastroenterol*. 2014;109:1304–11. <https://doi.org/10.1038/AJG.2014.29>
101. Möller SP, Apputhurai P, Tye-Din JA, Knowles SR. Quality of life in coeliac disease: relationship between psychosocial processes and



- quality of life in a sample of 1697 adults living with coeliac disease. *J Psychosom Res.* 2021;151:110652. <https://doi.org/10.1016/J.JPSYCHORES.2021.110652>
102. Paarlahti P, Kurppa K, Ukkola A, Collin P, Huhtala H, Mäki M, et al. Predictors of persistent symptoms and reduced quality of life in treated coeliac disease patients: a large cross-sectional study. *BMC Gastroenterol.* 2013;13:75. <https://doi.org/10.1186/1471-230X-13-75>
  103. van Megen F, Skodje GI, Stendahl M, Veierød MB, Lundin KEA, Henriksen C. High disease burden in treated celiac patients—a web-based survey. *Scand J Gastroenterol.* 2021;56:882–8. <https://doi.org/10.1080/00365521.2021.1930146>
  104. Parker S, Palsson O, Sanders DS, Simren M, Sperber AD, Törnblom H. Functional gastrointestinal disorders and associated health impairment in individuals with celiac disease. *Clin Gastroenterol Hepatol* Published online 2021. doi:<https://doi.org/10.1016/J.CGH.2021.07.026>
  105. Wolf RL, Lebowhl B, Lee AR, Zybert P, Reilly NR, Cadenhead J, et al. Hypervigilance to a gluten-free diet and decreased quality of life in teenagers and adults with celiac disease. *Dig Dis Sci.* 2018;63:1438–48. <https://doi.org/10.1007/S10620-018-4936-4>
  106. Ludvigsson JF, Lebowhl B, Chen Q, Bröms G, Wolf RL, Green PHR, et al. Anxiety after coeliac disease diagnosis predicts mucosal healing: a population-based study. *Aliment Pharmacol Ther.* 2018;48:1091–8. <https://doi.org/10.1111/APT.14991>
  107. Tio M, Cox MR, Eslick GD. Meta-analysis: coeliac disease and the risk of all-cause mortality, any malignancy and lymphoid malignancy. *Aliment Pharmacol Ther.* 2012;35(5):540–51. <https://doi.org/10.1111/J.1365-2036.2011.04972.X>
  108. Grainge MJ, West J, Solaymani-Dodaran M, Card TR, Logan RFA. The long-term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort study. *Aliment Pharmacol Ther.* 2012;35:730–9. <https://doi.org/10.1111/J.1365-2036.2012.04998.X>
  109. Ilus T, Kaukinen K, Virta LJ, Pukkala E, Collin P. Incidence of malignancies in diagnosed celiac patients: a population-based estimate. *Am J Gastroenterol.* 2014;109(9):1471–7. <https://doi.org/10.1038/AJG.2014.194>
  110. Emilsson L, Semrad C, Lebowhl B, Green PHR, Ludvigsson JF. Risk of small bowel adenocarcinoma, adenomas, and carcinoids in a Nationwide cohort of individuals with celiac disease. *Gastroenterology.* 2020;159(5):1686–1694.e2. <https://doi.org/10.1053/J.GASTRO.2020.07.007>
  111. Lebowhl B, Green PHR, Emilsson L, Mårild K, Söderling J, Roelstraete B, et al. Cancer risk in 47,241 individuals with celiac disease: a Nationwide cohort study. *Clin Gastroenterol Hepatol.* 2021;20:e111–31. <https://doi.org/10.1016/J.CGH.2021.05.034>
  112. Askling J, Linet M, Gridley G, Halstensen TS, Ekström K, Ekblom A. Cancer incidence in a population-based cohort of individuals hospitalized with celiac disease or dermatitis herpetiformis. *Gastroenterology.* 2002;123:1428–35. <https://doi.org/10.1053/GAST.2002.36585>
  113. West J, Logan RFA, Smith CJ, Hubbard RB, Card TR. Malignancy and mortality in people with coeliac disease: population based cohort study. *BMJ.* 2004;329:716–8. <https://doi.org/10.1136/BMJ.38169.486701.7C>
  114. Ludvigsson JF, West J, Ekblom A, Stephansson O. Reduced risk of breast, endometrial and ovarian cancer in women with celiac disease. *Int J Cancer.* 2012;131:E244–50. <https://doi.org/10.1002/IJC.26454>
  115. Elfström P, Granath F, Ye W, Ludvigsson JF. Low risk of gastrointestinal cancer among patients with celiac disease, inflammation, or latent celiac disease. *Clin Gastroenterol Hepatol.* 2012;10:30–6. <https://doi.org/10.1016/J.CGH.2011.06.029>
  116. Holmes GKT, Prior P, Lane MR, Pope D, Allan RN. Malignancy in coeliac disease—effect of a gluten free diet. *Gut.* 1989;30:333–8. <https://doi.org/10.1136/GUT.30.3.333>
  117. Dominguez Castro P, Harkin G, Hussey M, Christopher B, Kiat C, Liang Chin J, et al. Changes in presentation of celiac disease in Ireland from the 1960s to 2015. *Clin Gastroenterol Hepatol.* 2017;15(6):864–871.e3. <https://doi.org/10.1016/J.CGH.2016.11.018>
  118. Kivelä L, Kaukinen K, Lähdeaho ML, Huhtala H, Ashorn M, Ruuska T, et al. Presentation of celiac disease in Finnish children is no longer changing: a 50-year perspective. *J Pediatr.* 2015;167:1109–1115.e1. <https://doi.org/10.1016/J.JPEDI.2015.07.057>
  119. Muhammad H, Reeves S, Jeanes YM. Identifying and improving adherence to the gluten-free diet in people with coeliac disease. *Proc Nutr Soc.* 2019;78:418–25. <https://doi.org/10.1017/S002966511800277X>
  120. Biagi F, Schieppatti A, Maiorano G, Fraternali G, Agazzi S, Zingone F, et al. Risk of complications in coeliac patients depends on age at diagnosis and type of clinical presentation. *Dig Liver Dis.* 2018;50:549–52. <https://doi.org/10.1016/J.DLD.2017.12.001>
  121. Wijarnpreecha K, Lou S, Panjawanatan P, Cheungpasitporn W, Pungpapong S, Lukens FJ, et al. Cigarette smoking and risk of celiac disease: a systematic review and meta-analysis. *United European Gastroenterol J.* 2018;6:1285–93. <https://doi.org/10.1177/2050640618786790>
  122. Ukkola A, Mäki M, Kurppa K, Collin P, Huhtala H, Kekkonen L, et al. Changes in body mass index on a gluten-free diet in coeliac disease: a nationwide study. *Eur J Intern Med.* 2012;23:384–8. <https://doi.org/10.1016/J.EJIM.2011.12.012>
  123. Cheng J, Brar PS, Lee AR, Green PHR. Body mass index in celiac disease: beneficial effect of a gluten-free diet. *J Clin Gastroenterol.* 2010;44:267–71. <https://doi.org/10.1097/MCG.0B013E3181B7ED58>
  124. Grode L, Bech BH, Jensen TM, Humaidan P, Agerholm IE, Planaripoll O, et al. Prevalence, incidence, and autoimmune comorbidities of celiac disease: a nation-wide, population-based study in Denmark from 1977 to 2016. *Eur J Gastroenterol Hepatol.* 2018;30:83–91. <https://doi.org/10.1097/MEG.0000000000000092>
  125. Pavlovic M, Berenji K, Bukurov M. Screening of celiac disease in down syndrome—old and new dilemmas. *World J Clin Cases.* 2017;5:264–9. <https://doi.org/10.12998/WJCC.V5.I7.264>
  126. Mortensen KH, Cleemann L, Hjerrild BE, Nexø E, Loch H, Jeppesen EM, et al. Increased prevalence of autoimmunity in Turner syndrome—influence of age. *Clin Exp Immunol.* 2009;156:205–10. <https://doi.org/10.1111/J.1365-2249.2009.03895.X>
  127. Sultan AA, Crooks CJ, Card T, Tata LJ, Fleming KM, West J. Causes of death in people with coeliac disease in England compared with the general population: a competing risk analysis. *Gut.* 2015;64:1220–6. <https://doi.org/10.1136/GUTJNL-2014-308285>
  128. Quarpong W, Card TR, West J, Solaymani-Dodaran M, Logan RFA, Grainge MJ. Mortality in people with coeliac disease: long-term follow-up from a Scottish cohort. *United European Gastroenterol J.* 2019;7:377–87. <https://doi.org/10.1177/2050640618814662>
  129. Koskinen I, Virta LJ, Huhtala H, Ilus T, Kaukinen K, Collin P. Overall and cause-specific mortality in adult celiac disease and dermatitis herpetiformis diagnosed in the 21st century. *Am J Gastroenterol.* 2020;115:1117–24. <https://doi.org/10.14309/AJG.0000000000000665>

**How to cite this article:** Laurikka P, Kivelä L, Kurppa K, Kaukinen K. Systemic consequences of coeliac disease. *Aliment Pharmacol Ther.* 2022;56(Suppl. 1):64–72. <https://doi.org/10.1111/apt.16912>